Company Analysis - Altimmune's incretin drug, pemvidutide, shows promising prospects [1] - The company is awaiting the outcome of its end-of-phase 2 (EOP2) meeting with the U.S. FDA [1] Industry Focus - The biotech industry is heavily influenced by trial results and NDA/BLA approvals [2] - Companies in industries regulated by the FDA are a key focus area [2]

Altimmune (ALT 3.54%) had some encouraging news to share with the world as the trading week drew near a close on Thursday. The biotech announced that it will soon ascend to an important, specialized stock index; investors greeted this news by trading the company's stock up by more than 3% on the day. This provided quite a marked contrast to the general trend for stocks, as the S&P 500 index dipped marginally across the session.Inclusion in an industry indexBefore market open, Altimmune divulged that it is b ...

GAITHERSBURG, Md., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) effective prior to the market open on Monday, December 23, 2024. “Our addition to the NBI is an important recognition to conclude what has been a year of major progress for the Company,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. “With a number of significant in ...

Altimmune (NASDAQ: ALT ) is a small-cap biotech company bringing a GLP-1/Glucagon dual-agonist peptide called Pemvidutide to market. The company has pivoted multiple times in its history but is now casting a stake in obesity and MASH markets. IntenseI am a corporate strategy professional with work experience across industrials, energy, and technology. My primary investment interest is in biotech where I have over a decade of investment experience. My secondary investment interests are in dividend growth equ ...

Altimmune (ALT) is developing its lead candidate, pemvidutide, a novel, investigational and peptide-based GLP-1/glucagon dual receptor agonist for treating obesity and metabolic dysfunction-associated steatohepatitis (MASH).The company has made rapid progress with the development of pemvidutide, which has pushed up its stock price in recent months. A phase IIb IMPACT study is ongoing which is evaluating pemvidutide for the treatment of patients with biopsy-confirmed MASH.Last month, Altimmune completed the ...

Weekly subcutaneous doses of pemvidutide resulted in robust reductions in cardio-inflammatory, hepato-inflammatory and atherosclerotic lipids Findings support the potential benefit of pemvidutide on co-morbidities of metabolic dysfunction-associated steatohepatitis (MASH), including atherosclerosis, heart disease and metabolic syndrome Pemvidutide is currently being evaluated in IMPACT, the Phase 2b trial in subjects with MASH; data readout expected in Q2 2025 GAITHERSBURG, Md., Nov. 15, 2024 (GLOBE NEWSWIR ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

In my previous analysis of Altimmune, Inc. (NASDAQ: ALT ) in April 2024, I underscored the promising potential of its lead drug candidate, Pemvidutide [ALT-801]. This candidate is now quickly becoming an exciting complete treatment for obesity and metabolic-associated liver disease [MASLD/MASH]. Its GLP-1/glucagonMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-32587 ALTIMMUNE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 20-2726770 (State or ...

Altimmune, Inc. (NASDAQ:ALT) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Lee Roth - Burns McClellan, Investor Relations Advisors, Altimmune Vipin Garg - Chief Executive Officer Scott Harris - Chief Medical Officer Andrew Shutterly - Acting Chief Financial Officer Ray Jordt - Chief Business Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler Liisa Bayko - Evercore William Wood - B. Riley Securities Operator Good day, ladies and gentlemen, and welcome to ...